Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.

Journal article

BACKGROUND: BCG, the only licensed tuberculosis vaccine, affords poor protection against lung tuberculosis in infants and children. A new tuberculosis vaccine, which may enhance the BCG-induced immune response, is urgently needed. We assessed the safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic. METHODS:  Infants aged 5-12 months were vaccinated intradermally with either ...

Expand abstract

Authors: Scriba, T; Tameris, M; Mansoor, N; Smit, E; van der Merwe, L

• Publication status: Published
• Journal: Journal of infectious diseases
• Volume: 203
• Issue: 12
• Pages: 1832-1843
• Publication date: 2011-06-01
• DOI: 10.1093/infdis/jir195
• EISSN: 1537-6613
• ISSN: 0022-1899
• Language: English
• Keywords: Mycobacterium tuberculosis; Placebos; Age Factors; CD8-Positive T-Lymphocytes; Male; BCG Vaccine; Interferon-gamma; Acyltransferases; Tuberculosis; Humans; Female; Infant; Enzyme-Linked Immunospot Assay; Tuberculosis Vaccines; CD4-Positive T-Lymphocytes; Antigens, Bacterial; Dose-Response Relationship, Immunologic